Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

The impact of G-CSF on brentuximab vedotin plus chemotherapy in treating newly diagnosed advanced Hodgkin lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Treating newly diagnosed Hodgkin lymphoma

Treating newly diagnosed Hodgkin lymphoma

Posted by on Sep 13, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This overview discusses initial treatment options for classical Hodgkin lymphoma (cHL).  Some background Classical HL is a cancer of the lymph nodes. Early-stage (stage I/II) cHL is contained to half the body, while advanced (stage III/IV) has spread to both the upper and lower halves of the body. Both early and advanced cHL have...

Read More

Do survivors of childhood Hodgkin lymphoma have a risk of lung damage?

Do survivors of childhood Hodgkin lymphoma have a risk of lung damage?

Posted by on Aug 30, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the lung function of patients with classical Hodgkin lymphoma (HL) in the first years of remission. It found that these survivors had higher rates of lung damage. Some background HL is a cancer of the lymph nodes which most often affects children and young adults. HL has good outcomes, and most patients with HL will...

Read More

Brentuximab vedotin and bendamustine before stem cell transplant in relapsed or refractory classical Hodgkin lymphoma

Brentuximab vedotin and bendamustine before stem cell transplant in relapsed or refractory classical Hodgkin lymphoma

Posted by on Aug 30, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the real-world safety and effectiveness of brentuximab vedotin (BV) and bendamustine before stem cell transplant (SCT) for patients with relapsed or refractory classical Hodgkin lymphoma (cHL).  This study concluded that this treatment is safe and effective as...

Read More

The impact of checkpoint blockade therapy in making Hodgkin lymphoma sensitive to future treatment

The impact of checkpoint blockade therapy in making Hodgkin lymphoma sensitive to future treatment

Posted by on Aug 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated whether exposure to checkpoint blockade therapy (CBT) can make relapsed/refractory (R/R) Hodgkin lymphoma (HL) sensitive to further treatments. The main finding was that CBT may make patients with R/R-HL responsive to further treatments. Some background While a large percentage of patients with HL can ve cured with...

Read More

Allogeneic stem cell transplant in patients with classic Hodgkin lymphoma who have been treated with immune checkpoint inhibitors

Allogeneic stem cell transplant in patients with classic Hodgkin lymphoma who have been treated with immune checkpoint inhibitors

Posted by on Aug 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of allogeneic stem cell transplantation (alloSCT) after immune checkpoint inhibitor (ICI) treatment in patients with classic Hodgkin lymphoma (cHL).   This study concluded that this treatment is safe and has very good outcomes in these...

Read More

The effects of a second autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma after a first transplant

The effects of a second autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma after a first transplant

Posted by on Aug 9, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the outcomes of second autologous stem cell transplantation (ASCT2) in patients with relapsed/refractory Hodgkin lymphoma (r/r-HL) after a first transplantation (ASCT1). The main finding was that ASCT2 was safe and relatively effective in such patients. Some background ASCT replaces cancerous bone marrow with healthy...

Read More

COVID-19 with Cancer

COVID-19 with Cancer

Posted by on Jul 31, 2020 in Blog, Breast cancer, Colorectal cancer, Coronavirus / COVID-19, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...

Read More

Evaluating long-term pembrolizumab for relapsed Hodgkin lymphoma

Evaluating long-term pembrolizumab for relapsed Hodgkin lymphoma

Posted by on Jul 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the effect of pembrolizumab (Keytruda) to treat classical Hodgkin lymphoma (cHL) which had relapsed after previous treatments including brentuximab vedotin (Adcetris). It found that pembrolizumab was effective for these patients. Some background cHL is typically treated with chemotherapy, and sometimes with radiation...

Read More